Rhodojaponin IICAS# 26116-89-2 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 26116-89-2 | SDF | Download SDF |
| PubChem ID | 198051 | Appearance | Powder |
| Formula | C22H34O7 | M.Wt | 410.51 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Synonyms | Rhodojaponin III 6-acetate | ||
| Solubility | Soluble in DMSO and methanol; insoluble in water | ||
| SMILES | CC(=O)OC1CC23CC(C(C2O)CCC3C(C4C1(C(C5C4O5)(C)C)O)(C)O)(C)O | ||
| Standard InChIKey | FJISLLRXVSQIES-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H34O7/c1-10(23)28-13-8-21-9-19(4,25)11(16(21)24)6-7-12(21)20(5,26)15-14-17(29-14)18(2,3)22(13,15)27/h11-17,24-27H,6-9H2,1-5H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Rhodojaponin II correlates pretty well with cardiotoxicity. |
Rhodojaponin II Dilution Calculator
Rhodojaponin II Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.436 mL | 12.18 mL | 24.3599 mL | 48.7199 mL | 60.8999 mL |
| 5 mM | 0.4872 mL | 2.436 mL | 4.872 mL | 9.744 mL | 12.18 mL |
| 10 mM | 0.2436 mL | 1.218 mL | 2.436 mL | 4.872 mL | 6.09 mL |
| 50 mM | 0.0487 mL | 0.2436 mL | 0.4872 mL | 0.9744 mL | 1.218 mL |
| 100 mM | 0.0244 mL | 0.1218 mL | 0.2436 mL | 0.4872 mL | 0.609 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cyanidin-3,5-O-diglucoside chloride
Catalog No.:BCN3116
CAS No.:2611-67-8
- Chicago Sky Blue 6B
Catalog No.:BCC6816
CAS No.:2610-05-1
- Reneilmol
Catalog No.:BCN5135
CAS No.:260968-11-4
- Otilonium Bromide
Catalog No.:BCC4573
CAS No.:26095-59-0
- AMC
Catalog No.:BCC2837
CAS No.:26093-31-2
- Byakangelicol
Catalog No.:BCN5015
CAS No.:26091-79-2
- (-)-Oxypeucedanin
Catalog No.:BCC9244
CAS No.:26091-73-6
- Myrciaphenone A
Catalog No.:BCN7003
CAS No.:26089-54-3
- Sotetsuflavone
Catalog No.:BCN3846
CAS No.:2608-21-1
- 3-Isomangostin hydrate
Catalog No.:BCN5134
CAS No.:26063-96-7
- 1-Isomangostin hydrate
Catalog No.:BCN5133
CAS No.:26063-95-6
- Boc-Asp(OBzl)-ONp
Catalog No.:BCC3364
CAS No.:26048-69-1
- Picrasin B
Catalog No.:BCN5136
CAS No.:26121-56-2
- Madurensine
Catalog No.:BCN2092
CAS No.:26126-78-3
- 4-O-Feruloylquinic acid
Catalog No.:BCN3352
CAS No.:2613-86-7
- Frentizole
Catalog No.:BCC4035
CAS No.:26130-02-9
- Antiarol rutinoside
Catalog No.:BCN5137
CAS No.:261351-23-9
- MB05032
Catalog No.:BCC1731
CAS No.:261365-11-1
- Linderene
Catalog No.:BCN2779
CAS No.:26146-27-0
- Linderene acetate
Catalog No.:BCN8042
CAS No.:26146-28-1
- 3,5-Dihydroxybenzaldehyde
Catalog No.:BCN2257
CAS No.:26153-38-8
- Naproxen Sodium
Catalog No.:BCC6490
CAS No.:26159-34-2
- CGS 35066
Catalog No.:BCC5916
CAS No.:261619-50-5
- Denudatine
Catalog No.:BCN5406
CAS No.:26166-37-0
Diterpenoids from the flowers of Rhododendron molle.[Pubmed:15568787]
J Nat Prod. 2004 Nov;67(11):1903-6.
Five new grayanane-type diterpenoids, rhodomolleins IX (1), X (2), XI (3), XII (4), and XIII (5), a new kalmane-type diterpenoid, rhodomollein XIV (6), and seven known diterpenoids, grayanotoxin II, rhodomolleins I and XIX, rhodojaponins II, III, and VI (7), and kalmanol, were isolated from the flowers of Rhododendron molle. The structures of 1-6 were elucidated by spectroscopic methods, including 1D and 2D NMR experiments.
The integrated pharmacokinetics of major rhodojaponins correlates with the cardiotoxicity after oral administration of Rhododendri Mollis Flos extract in rats.[Pubmed:25256689]
J Ethnopharmacol. 2014 Nov 18;157:69-78.
ETHNOPHARMACOLOGICAL RELEVANCE: Rhododendri Mollis Flos (RMF), termed as Naoyanghua in Chinese, is a traditional anti-rheumatoid arthritis and bruises herb with associated cardiotoxicity. The predominant rhodojaponins occurring in RMF are responsible for its efficacy and toxicity. The narrow therapeutic window of rhodojaponins necessitates monitoring the pharmacokinetics and pharmacodynamics so as to ensure the safety in practical applications of RMF. MATERIALS AND METHODS: Fifty-four male Sprague-Dawley rats were divided into a control group, a low-dose group and a high-dose group. After oral administration of RMF extract, the cardiotoxicity of RMF was evaluated by assessing ventricular function and by measuring the plasma levels of LDH, CK-MB and AST. Then, an LC-MS method was established to determine the rat plasma concentrations of three major rhodojaponins including rhodojaponin I, II and III (R-I, II and III) and was applied to pharmacokinetic study. Finally, based on an AUC-weighting approach, the integrated pharmacokinetics of three rhodojaponins was determined. RESULTS: Compared with control group, cardiotoxicity was observed in RMF-treated rats with left ventricular dysfunction and with the continuously increased levels of LDH and CK-MB in a dose-dependent manner. The pharmacokinetic parameters (AUC0-t, AUC0-infinity, t1/2, Tmax and Cmax) for R-I, II and III were markedly different, and the integrated pharmacokinetics was therefore converted to describe the holistic pharmacokinetic profiles of R-I, II and III, which correlated pretty well with cardiotoxicity. CONCLUSIONS: It was found that myocardial damage was elicited by RMF extract in a dose-dependent manner and the plasma levels of LDH and CK-MB could reveal the severity of myocardial injury as potential markers. This study also highlighted the potential of integrated pharmacokinetics to provid a more comprehensive understanding of the relationship between the pharmacokinetic behaviors of traditional Chinese herbal medicine and its efficacy.
